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were formed by creatinine clearance measured from 24 h
urine (Table 1). For 13,905 patients who were over 18 years of
age, the number of patients from cut-off values of Scr and
estimated glomerular ﬁltration rate (eGFR) formula at each
CKD stage were compared. The four-variable Modiﬁcation of
Diet in Renal Disease Study equation using Japanese race
factor was applied for eGFR.3
The number of patients per CKD stage, which was
classiﬁed using the newly established Scr cut-off values,
showed very similar results to the number of patients
classiﬁed using eGFR cut-off values (Table 1). In conclusion,
setting the cut-off values would be necessary when applying
Scr to CKD.
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Nephroprevention in acute
phosphate nephropathy
To the Editor: We read the article by Markowitz and
Perazella,1 who masterfully show us the actuality of acute
phosphate nephropathy, this is probably a not uncommon
cause of kidney injury.
Lien2 previously referred to possible strategies to prevent
the side effects of phosphate overload, so we could establish a
preventive strategy:
(1) Avoid use in high-risk patients.1,2 (2) Use the minimal
effective dose,3 the total amount of phosphate excreted in the
urine after the second dose is threefold to fourfold to that
excreted after the ﬁrst dose; this suggests that the second dose
is particularly dangerous,4 so a reduction or replacement with
another agent (magnesium citrate or low-volume polyethy-
lene glycol) would be possible. (3) Increase the interval bet-
ween doses; a 24 h interval reduces the incidence of clinically
relevant hyperphosphatemia, with no loss of efﬁcacy com-
pared with an interval of 9–12 h.3 (4) Avoid dehydration;1,2
clear ﬂuid should be administered; in some centers Gatorade
or E-lyte is recommended (possibly a superior alternative).
Furthermore, monitoring of body weight and urine color is
useful to guide ﬂuid intake. During the procedure an
intravenous line is routinely placed and normal saline could
be given during and after the procedure. (5) Perform serum
biochemistry tests before colonoscopy and measure the renal
function and baseline electrolytes; in high-risk or unstable
patients a control 2 or 3 days after would be necessary. (6)
Finally, consider an alternative bowel-cleansing agent.
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Cognitive-behavioral group
therapy is an effective treatment
for major depression in
hemodialysis (HD) patients
To the Editor: We read with great interest the article by
Duarte et al.1 evaluating a randomized trial on cognitive-
behavioral group therapy (CBT) for major depression in
hemodialysis (HD) patients. In this study group, receiving
CBT had signiﬁcant improvements, compared with the control
group, in the average scores on the Beck Depression Inventory
and Mini-International Psychiatric Interview, and in several
Kidney Disease Quality of Life-Short Form (KDQOL-SF)
dimensions up to 9 months. We would like to raise two issues.
The authors addressed most of the clinical characteristics that
could affect depression in HD patients, with the exception of
one: chronic pain. Chronic pain is a signiﬁcant problem for
B50% of HD patients. The impact of chronic pain on
Table 1 | Number of patients in CKD stage according to the
values of eGFR and Scr cut-off
eGFR (ml/min per 1.73m2) Scr (mg/dl)
CKD stage Cut-off No. (%) Cut-off No. (%)
1 X90 5156 (37.1) p0.7 5767 (41.5)
2 60–89 6990 (50.3) 0.8–1.0 6159 (44.3)
3 30–59 1360 (9.78) 1.1–1.6 1505 (10.8)
4 15–29 172 (1.24) 1.7–2.5 196 (1.41)
5 o15 227 (1.62) 42.5 278 (1.99)
13,905 (100) 13,905 (100)
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration
rate; Scr, serum creatinine.
646 Kidney International (2010) 77, 645–650
l e t te r to the ed i to r
depression was already conﬁrmed.2 Moreover, it may predis-
pose patients to consider withdrawal of dialysis. We performed
a cross-sectional study (n¼ 205) evaluating the prevalence of
pain among a cohort of long-term HD patients and compared
depression (Hospital Anxiety and Depression Scale (HADS))
and quality of life (Version 2.0 of Short Form 36 (SF-36)) in
patients with and without chronic pain.3 The results are
summarized in Table 1. Signiﬁcant differences were found in
anxiety (HADS-A), depression (HADS-D), and all SF-36 scales.
Patients with pain showed higher levels of calcium-phosphorus
ion product and parathyroid hormone than those without pain.
Perhaps those with pain and depression are more non-adherent
to dietary and ﬂuid restriction, which in turn may lead to worse
outcomes in the future.4 Data on pain prevalence or even the
subanalysis in the study by the Duarte group would be
interesting. Some data about pain are in KDQOL-SF (body
pain).
While investigating the problem of how to create coping
strategies to deal with dialysis treatment, depression, and pain,
we found in our study some differences between patients who
were on the waiting list for kidney transplantation and those
who were not on the list (Traﬁdło et al.; www.abstracts2view.
com/wcn). HD patients with chronic pain evidenced that being
on the waiting list was associated with diminished cognitive/
behavioral scores in the Pain Coping Strategies Questionnaire
(less catastrophizing; P¼ 0.009). A similar comparison addres-
sing depression-coping strategies would be important.
Finally, we appreciate Duarte et al. for the ﬁrst randomized
trial on CBT in the HD population and also encourage
nephrologists to pay more attention to diagnosing and
treating depression in HD patients because it may be essential
in pain management.
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The Authors Reply: We appreciate the interest in our
recently published article ‘Cognitive-behavioral group therapy
is an effective treatment for major depression in hemodialysis
(HD) patients’, which presented the advantages of a speciﬁc
psychological approach to treat depression in Brazilian
patients undergoing hemodialysis.1,2 The authors recognize
the importance of studying in more depth the relationship of
physical symptoms, such as pain, in chronic kidney disease
and its treatment, with both the functional status and the
psychosocial well-being of these patients.
The prevalence of chronic pain in patients of our study
was high. At the beginning of the study, the percentage of
patients with body pain was similar in the two study groups:
84.8% (n¼ 39) in the cognitive-behavioral therapy group
and 84.1% (n¼ 37) in the control group. After 3 months,
this prevalence rate decreased in the intervention group
(78.0% (n¼ 32)) and increased in the control group (88.6%
(n¼ 39)). Muscle pain was present in 71.7% (n¼ 33) and
72.7% (n¼ 32) of the patients in the intervention and the
control groups, respectively, at baseline. The corresponding
ﬁgures after 3 months of study were 73.2 and 72.7%,
respectively. Seventy-two percent (n¼ 33) of the patients in
the intervention group and 72.7% (n¼ 32) of the patients in
the control group stated at baseline that the pain interfered
Table 1 | A comparison of HD patients with and without pain
No pain
(n=75)
Chronic pain
(n=130)
ANOVA
Mean s.d. Mean s.d. P
Maintenance HD (months) 36.1 43.3 64.9 67.8 0.0011
Age (years) 62.7 14.1 58.9 13.6 0.0598
24 h diuresis (l) 0.5 0.5 0.3 0.5 0.0065
BMI 25.0 4.1 25.4 4.2 0.4855
SBP before HD (mmHg) 136.4 26.5 133.8 24.7 0.4797
DBP before HD (mmHg) 77.7 11.0 76.0 11.2 0.3014
SBP after HD (mmHg) 131.3 25.7 126.6 26.4 0.2175
DBP after HD (mmHg) 75.5 11.9 73.8 12.3 0.3368
Total protein (g/l) 6.9 0.6 7.0 0.6 0.1406
Albumin (g/l) 3.6 0.4 3.7 0.5 0.1526
Hemoglobin (g/l) 10.6 1.6 11.1 2.8 0.2135
CaxP 47.2 17.1 53.1 17.3 0.0190
PTH 215.6 181.6 467.0 595.9 0.0004
kt/V 1.1 0.2 1.2 0.3 0.1710
kt/V weekly 3.4 0.6 3.5 0.6 0.1543
Mean UF 2610.7 857.9 2706.9 844.7 0.4354
CRP (g/l) 12.1 15.0 14.2 23.7 0.4990
HADS-A 4.3 3.4 6.5 3.4 0.0000
HADS-D 4.6 4.0 6.8 4.1 0.0002
MMSE 25.6 3.1 27.2 7.5 0.2559
SF-36v2
GH 49.1 19.6 38.4 17.7 0.0001
BP 86.8 22.0 44.5 25.6 0.0000
PF 52.6 31.7 36.6 29.8 0.0004
RP 57.4 44.3 40.5 43.1 0.0088
RE 70.8 42.6 58.5 45.4 0.0624
VT 59.2 22.4 44.1 19.7 0.0000
MH 69.9 19.2 59.2 20.6 0.0003
SF 77.4 26.0 59.5 28.4 0.0000
Abbreviations: ANOVA, analysis of variance; BMI, body mass index; BP, bodily pain;
CaxP, calcium-phosphorus ion product; CRP, C-reactive protein; DBP, diastolic blood
pressure; GH, general health; HADS, Hospital Anxiety and Depression Scale; HD,
hemodialysis; MH, mental health; MMSE, Mini-Mental State Examination; PF, physical
functioning; PTH, parathyroid hormone; RE, role-emotional limitation; RP, role-physical
limitation; SBP, systolic blood pressure; SF, social functioning; SF-36v2, Version 2.0 of
Short Form 36; UF, ultrafiltration; VT, vitality.
The bold values indicate statistically significant difference (Po0.05).
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